TIDMFDBK

RNS Number : 5643E

Feedback PLC

06 November 2020

The following amendments have been made to the 'Result of Annual General Meeting' announcement released on 5 November 2020 at 1.23 pm under RNS No 4187E.

The 'Total Votes Cast' column in the table below has been updated to show the correct figures. All other details remain unchanged. The full amended text is shown below.

Feedback plc

Result of Annual General Meeting - Amendment

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that at its annual general meeting held earlier today, all resolutions were duly passed on a poll. The proxy voting results of the resolutions are included below.

 
 Resolutions                Votes For*    % of      Votes       % of votes   Votes        Total votes 
                                           votes     Against     cast**       Withheld**   cast** 
                                           cast** 
 
 1. To receive 
  and adopt the 
  annual report 
  and accounts for 
  the year ended 
  31 May 2020               504,134,927   100.00%       -         0.00%        22,000     504,134,927 
                           ------------  --------  ----------  -----------  ------------  ----------- 
 
 2. To elect Adam 
  Denning as a director    504,152,622   100.00%     3,305        0.00%        1,000      504,155,927 
                           ------------  --------  ----------  -----------  ------------  ----------- 
 
 3. To elect Philipp 
  Prince as a director     479,902,622    95.19%   24,253,305     4.81%        1,000      504,155,927 
                           ------------  --------  ----------  -----------  ------------  ----------- 
 
 4. To re-elect 
  Simon Sturge as 
  a director               504,152,486   100.00%     3,441        0.00%        1,000      504,155,927 
                           ------------  --------  ----------  -----------  ------------  ----------- 
 
 5. To appoint 
  Price Bailey LLP 
  as auditors of 
  the Company              504,118,963    99.99%     36,964       0.01%        1,000      504,155,927 
                           ------------  --------  ----------  -----------  ------------  ----------- 
 
 6. To authorise 
  the directors 
  to allot relevant 
  securities equivalent 
  to up to two thirds 
  of the Company's 
  issued share capital, 
  subject to certain 
  conditions               504,027,372   100.00%     3,305        0.00%       126,250     504,030,677 
                           ------------  --------  ----------  -----------  ------------  ----------- 
 
 7. To authorise 
  the directors 
  to allot relevant 
  securities equivalent 
  to up to 10 per 
  cent. of the Company's 
  issued share capital 
  on a non-pre-emptive 
  basis subject 
  to certain conditions    478,945,731    95.01%   25,135,091     4.99%        76,205     504,080,822 
                           ------------  --------  ----------  -----------  ------------  -----------

Notes:

* "Votes For" include votes giving the Chairman discretion.

** "Votes Withheld" are not votes in law and do not count in the number of votes counted for or against a resolution, or towards the total votes cast.

-Ends-

Enquiries:

 
 Feedback plc                          +44 (0)1954 718072 
  Tom Oakley, CEO                       IR@fbk.com 
  Lindsay Melvin, CFO 
 
 Allenby Capital Limited (Nominated 
  Adviser) 
  David Worlidge / Asha Chotai         +44 (0)20 3328 5656 
 
 Peterhouse Capital Limited (Joint 
  Broker) 
  Lucy Williams / Duncan Vasey         +44 (0)20 7469 0936 
 
 Stanford Capital Partners Limited 
  (Joint Broker) 
  Patrick Claridge / John Howes        +44 20 3815 8880 
 
 Walbrook PR Ltd                       Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 
 Paul McManus/Nick Rome/Nicholas       07980 541 893 or 07748 325 236 or 
  Johnson                               07884 664 686

Notes to Editors

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGGZMGMKVGGGZM

(END) Dow Jones Newswires

November 06, 2020 10:03 ET (15:03 GMT)

Feedback (LSE:FDBK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Feedback Charts.
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Feedback Charts.